InvestSMART

Immutep Limited (ASX: IMM) - Announcements

- Current share price for IMM : $0.023

ASX company news and announcements for Immutep Limited (IMM) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Immutep Limited (IMM) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Immutep Limited (IMM), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Immutep Limited (IMM)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$34 Immutep Investor Update 17 Jun 2022 12:38PM $0.305 $0.023 fallen by 92.46%
$34 Webcast slides for 1st line NSCLC data from TACTI-002 trial 6 Jun 2022 9:04AM $0.430 $0.023 fallen by 94.65%
$34 Positive ORR in 1st line NSCLC from ph 2 TACTI-002 trial 6 Jun 2022 8:20AM $0.430 $0.023 fallen by 94.65%
$34 Immutep webcast for TACTI-002 data presented at ASCO 2022 2 Jun 2022 8:17AM $0.420 $0.023 fallen by 94.52%
$34 Immutep announces publication of ASCO 2022 abstracts 27 May 2022 7:34AM $0.390 $0.023 fallen by 94.10%
$34 Immutep Corporate Presentation 24 May 2022 5:28PM $0.385 $0.023 fallen by 94.03%
$34 Immutep to Present at Investor Conferences 20 May 2022 8:22AM $0.385 $0.023 fallen by 94.03%
$34 Leading Oncologists appointed to Clinical Advisory Board 18 May 2022 8:17AM $0.380 $0.023 fallen by 93.95%
$34 New & significant data from AIPAC phase 2b trial in MBC 4 May 2022 6:54PM $0.330 $0.023 fallen by 93.03%
$34 Quarterly Activities/Appendix 4C Cash Flow Report 29 Apr 2022 8:01AM $0.325 $0.023 fallen by 92.92%
$34 Immutep to announce new TACTI-002 data at ASCO 2022 28 Apr 2022 8:22AM $0.315 $0.023 fallen by 92.70%
$34 Change in substantial holding 8 Apr 2022 8:20AM $0.360 $0.023 fallen by 93.61%
$34 Efti with Keytruda shows encouraging activity in lung cancer 30 Mar 2022 8:24AM $0.380 $0.023 fallen by 93.95%
$34 Immutep announces publication of ELCC 2022 abstract 24 Mar 2022 8:19AM $0.445 $0.023 fallen by 94.83%
$34 Immutep to present Phase IIb breast cancer data at ESMO 2022 18 Mar 2022 4:18PM $0.395 $0.023 fallen by 94.18%
$34 Japanese patent granted for LAG-3 antibody LAG525 18 Mar 2022 3:36PM $0.400 $0.023 fallen by 94.25%
$34 Change in substantial holding 16 Mar 2022 8:23AM $0.360 $0.023 fallen by 93.61%
$34 Application for quotation of securities - IMM 11 Mar 2022 9:26AM $0.400 $0.023 fallen by 94.25%
$34 Immutep receives FDA feedback for Efti development in MBC 10 Mar 2022 8:25AM $0.390 $0.023 fallen by 94.10%
$34 Initial Director's Interest Notice - Lucy Turnbull 25 Feb 2022 3:51PM $0.348 $0.023 fallen by 93.38%
$34 Proposed issue of securities - IMM 25 Feb 2022 3:42PM $0.345 $0.023 fallen by 93.33%
$34 Appointment of Non-Executive Director 25 Feb 2022 8:01AM $0.343 $0.023 fallen by 93.28%
$34 Immutep to Present at Healthcare Investor Conferences 24 Feb 2022 8:01AM $0.355 $0.023 fallen by 93.52%
$34 Half Yearly Report and Accounts 23 Feb 2022 6:22PM $0.355 $0.023 fallen by 93.52%
$34 Immutep to present new data from TACTI-002 at ELCC 2022 18 Feb 2022 8:13AM $0.370 $0.023 fallen by 93.78%

376 - 400 of 798 results

Page 16 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.